-
Something wrong with this record ?
Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation
K. Horska, H. Kotolova, M. Karpisek, Z. Babinska, T. Hammer, J. Prochazka, T. Stark, V. Micale, J. Ruda-Kucerova
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Antipsychotic Agents pharmacology therapeutic use MeSH
- Haloperidol pharmacology therapeutic use MeSH
- Lipid Metabolism drug effects MeSH
- Metabolome drug effects MeSH
- Methylazoxymethanol Acetate analogs & derivatives MeSH
- Disease Models, Animal * MeSH
- Olanzapine pharmacology therapeutic use MeSH
- Rats, Sprague-Dawley MeSH
- Risperidone pharmacology therapeutic use MeSH
- Schizophrenia chemically induced drug therapy metabolism MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Mortality in psychiatric patients with severe mental illnesses reaches a 2-3 times higher mortality rate compared to the general population, primarily due to somatic comorbidities. A high prevalence of cardiovascular morbidity can be attributed to the adverse metabolic effects of atypical antipsychotics (atypical APs), but also to metabolic dysregulation present in drug-naïve patients. The metabolic aspects of neurodevelopmental schizophrenia-like models are understudied. This study evaluated the metabolic phenotype of a methylazoxymethanol (MAM) schizophrenia-like model together with the metabolic effects of three APs [olanzapine (OLA), risperidone (RIS) and haloperidol (HAL)] administered via long-acting formulations for 8 weeks in female rats. Body weight, feed efficiency, serum lipid profile, gastrointestinal and adipose tissue-derived hormones (leptin, ghrelin, glucagon and glucagon-like peptide 1) were determined. The lipid profile was assessed in APs-naïve MAM and control cohorts of both sexes. Body weight was not altered by the MAM model, though cumulative food intake and feed efficiency was lowered in the MAM compared to CTR animals. The effect of the APs was also present; body weight gain was increased by OLA and RIS, while OLA induced lower weight gain in the MAM rats. Further, the MAM model showed lower abdominal adiposity, while OLA increased it. Serum lipid profile revealed MAM model-induced alterations in both sexes; total, HDL and LDL cholesterol levels were increased. The MAM model did not exert significant alterations in hormonal parameters except for elevation in leptin level. The results support intrinsic metabolic dysregulation in the MAM model in both sexes, but the MAM model did not manifest higher sensitivity to metabolic effects induced by antipsychotic treatment.
National Institute of Mental Health Topolova 748 250 67 Klecany Czech Republic
R and D Department Biovendor Laboratorni Medicina Karasek 1 621 00 Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21011962
- 003
- CZ-PrNML
- 005
- 20210507104929.0
- 007
- ta
- 008
- 210420s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.taap.2020.115214 $2 doi
- 035 __
- $a (PubMed)32866524
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Horska, Katerina $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho trida 1946/1, 612 00 Brno, Czech Republic; Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Palackeho trida 1946/1, 612 00 Brno, Czech Republic
- 245 10
- $a Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation / $c K. Horska, H. Kotolova, M. Karpisek, Z. Babinska, T. Hammer, J. Prochazka, T. Stark, V. Micale, J. Ruda-Kucerova
- 520 9_
- $a Mortality in psychiatric patients with severe mental illnesses reaches a 2-3 times higher mortality rate compared to the general population, primarily due to somatic comorbidities. A high prevalence of cardiovascular morbidity can be attributed to the adverse metabolic effects of atypical antipsychotics (atypical APs), but also to metabolic dysregulation present in drug-naïve patients. The metabolic aspects of neurodevelopmental schizophrenia-like models are understudied. This study evaluated the metabolic phenotype of a methylazoxymethanol (MAM) schizophrenia-like model together with the metabolic effects of three APs [olanzapine (OLA), risperidone (RIS) and haloperidol (HAL)] administered via long-acting formulations for 8 weeks in female rats. Body weight, feed efficiency, serum lipid profile, gastrointestinal and adipose tissue-derived hormones (leptin, ghrelin, glucagon and glucagon-like peptide 1) were determined. The lipid profile was assessed in APs-naïve MAM and control cohorts of both sexes. Body weight was not altered by the MAM model, though cumulative food intake and feed efficiency was lowered in the MAM compared to CTR animals. The effect of the APs was also present; body weight gain was increased by OLA and RIS, while OLA induced lower weight gain in the MAM rats. Further, the MAM model showed lower abdominal adiposity, while OLA increased it. Serum lipid profile revealed MAM model-induced alterations in both sexes; total, HDL and LDL cholesterol levels were increased. The MAM model did not exert significant alterations in hormonal parameters except for elevation in leptin level. The results support intrinsic metabolic dysregulation in the MAM model in both sexes, but the MAM model did not manifest higher sensitivity to metabolic effects induced by antipsychotic treatment.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antipsychotika $x farmakologie $x terapeutické užití $7 D014150
- 650 12
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a haloperidol $x farmakologie $x terapeutické užití $7 D006220
- 650 _2
- $a metabolismus lipidů $x účinky léků $7 D050356
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metabolom $x účinky léků $7 D055442
- 650 _2
- $a methylazoxymethanolacetát $x analogy a deriváty $7 D008746
- 650 _2
- $a olanzapin $x farmakologie $x terapeutické užití $7 D000077152
- 650 _2
- $a potkani Sprague-Dawley $7 D017207
- 650 _2
- $a risperidon $x farmakologie $x terapeutické užití $7 D018967
- 650 _2
- $a schizofrenie $x chemicky indukované $x farmakoterapie $x metabolismus $7 D012559
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kotolova, Hana $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho trida 1946/1, 612 00 Brno, Czech Republic; Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Palackeho trida 1946/1, 612 00 Brno, Czech Republic
- 700 1_
- $a Karpisek, Michal $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho trida 1946/1, 612 00 Brno, Czech Republic; Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Palackeho trida 1946/1, 612 00 Brno, Czech Republic; R&D Department, Biovendor - Laboratorni Medicina, Karasek 1, 621 00 Brno, Czech Republic
- 700 1_
- $a Babinska, Zuzana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
- 700 1_
- $a Hammer, Tomas $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho trida 1946/1, 612 00 Brno, Czech Republic; Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Palackeho trida 1946/1, 612 00 Brno, Czech Republic
- 700 1_
- $a Prochazka, Jiri $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho trida 1946/1, 612 00 Brno, Czech Republic; Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Palackeho trida 1946/1, 612 00 Brno, Czech Republic
- 700 1_
- $a Stark, Tibor $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic; Department of Stress Neurobiology and Neurogenetics, Neuronal Plasticity Group, Max Planck Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany
- 700 1_
- $a Micale, Vincenzo $u Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Via Santa Sofia 97, I-95123 Catania, Italy; National Institute of Mental Health, Topolova 748, 250 67 Klecany, Czech Republic
- 700 1_
- $a Ruda-Kucerova, Jana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic. Electronic address: jkucer@med.muni.cz
- 773 0_
- $w MED00010691 $t Toxicology and applied pharmacology $x 1096-0333 $g Roč. 406, č. - (2020), s. 115214
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32866524 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507104927 $b ABA008
- 999 __
- $a ok $b bmc $g 1650357 $s 1132341
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 406 $c - $d 115214 $e 20200829 $i 1096-0333 $m Toxicology and applied pharmacology $n Toxicol Appl Pharmacol $x MED00010691
- LZP __
- $a Pubmed-20210420
